Status:
COMPLETED
Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Early-stage Breast Cancer
Pain Syndrome
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
The REaCT TAPS clinical trial will compare a tapering dose of dexamethasone to other standards of care on the presence of taxane-associated pain syndrome (TAPS) in early stage breast cancer.
Detailed Description
Taxanes such as docetaxel and paclitaxel are widely used chemotherapeutic agents in patients with early stage breast cancer and is commonly associated with taxane-associated pain syndrome (TAPS). TAPS...
Eligibility Criteria
Inclusion
- Patients receiving docetaxel-based chemotherapy (Docetaxel 75mg/m2 and cyclophosphamide once every 21 days; or Docetaxel 75mg/m2 and carboplatin and trastuzumab once every 21 days or Fluoro-uracil, epirubicin and cyclophosphamide for 3 cycles once every 21 days, then docetaxel 100mg/m2 once every 21 days; or Adriamycin and cyclophosphamide for 3 cycles, then docetaxel 100mg/m2 once every 21 days) for early stage breast cancer.
- English literacy and ability to complete questionnaire
- ≥19 years of age
Exclusion
- Contraindication to dexamethasone
- Unable to give informed consent
- Prior receipt of taxane-based chemotherapy
- Patient has a significant emotional or psychiatric disorder that in the opinion of the investigator precludes study entry.
Key Trial Info
Start Date :
February 28 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2019
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT03348696
Start Date
February 28 2018
End Date
April 2 2019
Last Update
January 9 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Southlake Regional Cancer Centre
Newmarket, Ontario, Canada
2
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada, k1H 8L6